Tirabrutinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Hodgkins Lymphoma
Conditions
Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Trial Timeline
Aug 17, 2012 → Jan 11, 2016
NCT ID
NCT01659255About Tirabrutinib
Tirabrutinib is a phase 1 stage product being developed by Ono Pharmaceutical for Non Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01659255. Target conditions include Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07198087 | Phase 1 | Recruiting |
| NCT01659255 | Phase 1 | Completed |
Competing Products
18 competing products in Non Hodgkins Lymphoma